{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:51:39Z","timestamp":1791409899799,"version":"4.3.3"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["97-03-33-40295"],"award-info":[{"award-number":["97-03-33-40295"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT105021"],"award-info":[{"award-number":["WT105021"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110391","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T06:04:53Z","timestamp":1786773893000},"page":"110391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of 3-[(5-nitro-2-heteroaryl)methylene]-2-indolinone derivatives as highly potent antileishmanial agents and their bioactivation by NTR1 and 2"],"prefix":"10.1016","volume":"181","author":[{"given":"Seyyed Hasan","family":"Shariatmadari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Lopes","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wyllie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latifeh","family":"Navidpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110391_bb0005","article-title":"Leishmaniasis","author":"World Health Organization","year":"2023","journal-title":"Key facts."},{"key":"10.1016\/j.bioorg.2026.110391_bb0010","article-title":"Leishmania: an urgent need for new treatments","volume":"87","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bioorg.2026.110391_bb0015","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.3390\/cells10113195","article-title":"Cell cycle, telomeres, and telomerase in leishmania spp.: what do we know so far?","volume":"10","author":"Assis","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.110391_bb0020","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.110391_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms10101887","article-title":"Visceral leishmaniasis: epidemiology, diagnosis, and treatment regimens in different geographical areas with a focus on pediatrics","volume":"10","author":"Scarpini","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.bioorg.2026.110391_bb0030","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1039\/D1MD00362C","article-title":"Current leishmaniasis drug discovery","volume":"13","author":"Pinheiro","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110391_bb0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.drudis.2017.09.006","article-title":"Molecular targets and pathways for the treatment of visceral leishmaniasis","volume":"23","author":"Jain","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2026.110391_bb0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.actatropica.2015.12.016","article-title":"Visceral leishmaniasis: revisiting current treatments and approaches for future discoveries","volume":"155","author":"No","year":"2016","journal-title":"Acta Trop."},{"key":"10.1016\/j.bioorg.2026.110391_bb0045","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/514704","article-title":"Lipid formulations of amphotericin B: clinical efficacy and toxicities","volume":"27","author":"Annie","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bioorg.2026.110391_bb0050","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1179\/joc.2001.13.5.461","article-title":"Renal transport of antibiotics and nephrotoxicity: a review","volume":"13","author":"Fanos","year":"2001","journal-title":"J. Chemother."},{"key":"10.1016\/j.bioorg.2026.110391_bb0055","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bioorg.2026.110391_bb0060","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejmech.2018.08.012","article-title":"An update on small molecule strategies targeting leishmaniasis","volume":"157","author":"Kapil","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110391_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111842","article-title":"Oxindole and its derivatives: a review on recent progress in biological activities","volume":"141","author":"Khetmalis","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.110391_bb0070","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ejmech.2016.08.011","article-title":"Oxindole: a chemical prism carrying plethora of therapeutic benefits","volume":"123","author":"Kaur","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110391_bb0075","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.bmc.2013.12.039","article-title":"Direct synthesis of C3-mono-functionalized oxindoles from N-unprotected 2-oxindole and their antileishmanial activity","volume":"22","author":"Scala","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110391_bb0080","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bmcl.2018.02.023","article-title":"Synthesis and biological evaluation of polyhydroxylated oxindole derivatives as potential antileishmanial agent","volume":"28","author":"Yousuf","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110391_bb0085","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/futurepharmacol4010015","article-title":"Using 5-nitroimidazole derivatives against neglected tropical protozoan diseases: systematic review","volume":"4","author":"Vichi-Ram\u00edrez","year":"2024","journal-title":"Future Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110391_bb0090","doi-asserted-by":"crossref","first-page":"32376","DOI":"10.1039\/C5RA02669E","article-title":"Antileishmanial drug discovery: comprehensive review of the last 10 years","volume":"5","author":"Sangshetti","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110391_bb0095","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ejmech.2017.01.022","article-title":"Design, synthesis, structure-activity relationship and mechanism of action studies of a series of 4-chloro-1-phthalazinyl hydrazones as a potent agent against leishmania braziliensis","volume":"127","author":"Romero","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110391_bb0100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejmech.2018.07.064","article-title":"8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases","volume":"157","author":"Fersing","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110391_bb0105","first-page":"637","article-title":"Further investigations of Nitroheterocyclic compounds as potential Antikinetoplastid drug candidates","volume":"13","author":"Garc\u00eda-Estrada","year":"2023","journal-title":"Biomol"},{"key":"10.1016\/j.bioorg.2026.110391_bb0110","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1021\/acs.jmedchem.7b01581","article-title":"Development of (6R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (DNDI-8219): a new Lead for visceral leishmaniasis","volume":"61","author":"Thompson","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110391_bb0115","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00583-22","article-title":"Antileishmanial activities of (Z)-2-(nitroimidazolylmethylene)-3(2H)-benzofuranones: synthesis, in vitro assessment and bioactivation by NTR 1 and 2","volume":"66","author":"Navidpour","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2026.110391_bb0120","author":"SynArchive"},{"key":"10.1016\/j.bioorg.2026.110391_bb0125","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1080\/00397919408010603","article-title":"A new efficient and mild synthesis of 2-Sxindoles by one-pot Wolff-Kishner like reduction of Isatin derivatives","volume":"24","author":"Crestini","year":"1994","journal-title":"Synth. Commun."},{"key":"10.1016\/j.bioorg.2026.110391_bb0130","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jhet.5570290461","article-title":"Nitroimidazoles. IX. Synthesis of 2-acetyl-1-methyl-5-nitroimidazole","volume":"29","author":"Shafiee","year":"1992","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.bioorg.2026.110391_bb0135","first-page":"1033","volume":"5","author":"Wahl","year":"1909","journal-title":"Bull. Soc. Chim. Fr."},{"key":"10.1016\/j.bioorg.2026.110391_bb0140","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.bmc.2010.01.011","article-title":"Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors","volume":"18","author":"Mologni","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110391_bb0145","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1021\/jm980123i","article-title":"Synthesis and biological evaluations of 3-substituted Indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases","volume":"41","author":"Sun","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110391_bb0150","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1550-7408.1977.tb00987.x","article-title":"New culture medium for maintenance of tsetse tissues and growth of trypanosomatids","volume":"24","author":"Cunningham","year":"1997","journal-title":"J. Protozool."},{"key":"10.1016\/j.bioorg.2026.110391_bb0155","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.41.5.972","article-title":"Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents","volume":"41","author":"Sereno","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2026.110391_bb0160","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00436-002-0695-3","article-title":"A simple and reproducible method to obtain large numbers of axenic amastigotes of different leishmania species","volume":"88","author":"Teixeira","year":"2002","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.bioorg.2026.110391_bb0165","first-page":"555","article-title":"Toxicity of nitro compounds toward hypoxic mammalian cells in vitro: dependence on reduction potential","volume":"64","author":"Adams","year":"1980","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bioorg.2026.110391_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135556","article-title":"Antiprotozoal activity profiling of approved drugs: a starting point toward drug repositioning","volume":"10","author":"Kaiser","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2026.110391_bb0175","article-title":"Pharmacokinetics and pharmacodynamics of the nitroimidazole DNDI-0690 in mouse models of cutaneous leishmaniasis","volume":"23","author":"Wijnant","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2026.110391_bb0180","first-page":"31","article-title":"Action of clinically utilized 5-nitroimidazoles on microorganisms","volume":"26","author":"M\u00fcller","year":"1981","journal-title":"Scand. J. Infect. Dis. Suppl."},{"key":"10.1016\/j.bioorg.2026.110391_bb0185","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1128\/AAC.02398-12","article-title":"Comparison of a high-throughput high-content intracellular leishmania donovani assay with an axenic amastigote assay","volume":"57","author":"Rycker","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2026.110391_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110391_bb0195","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/AAC.01788-12","article-title":"Assessing the essentiality of leishmania donovani nitroreductase and its role in nitro drug activation","volume":"57","author":"Wyllie","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2026.110391_bb0200","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/biom11020267","article-title":"Nitroaromatic antibiotics as nitrogen oxide sources","volume":"11","author":"Rice","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2026.110391_bb0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0166-6851(03)00142-7","article-title":"An in vitro system for developmental and genetic studies of leishmania donovani phosphoglycans","volume":"130","author":"Goyard","year":"2003","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.bioorg.2026.110391_bb0210","first-page":"473","article-title":"A new fluorometric assay for cytotoxicity measurements in vitro","volume":"3","author":"Page","year":"1993","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2026.110391_bb0215","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1383-5769(99)00020-3","article-title":"A simple colorimetric method to screen drug cytotoxicity against leishmania using the dye Alamar blue\u00ae","volume":"48","author":"Mikus","year":"2000","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.bioorg.2026.110391_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005971","article-title":"Activation of bicyclic nitro-drugs by a novel Nitroreductase (NTR2) in leishmania","volume":"12","author":"Wyllie","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bioorg.2026.110391_bb0225","doi-asserted-by":"crossref","first-page":"119re1","DOI":"10.1126\/scitranslmed.3003326","article-title":"The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis","volume":"4","author":"Wyllie","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2026.110391_bb0230","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0022-1759(94)90396-4","article-title":"A new rapid and simple non-radioactive assay to monitor and determine proliferation of lymphocytes. An alternative to [3H]thymidine incorporation assay","volume":"179","author":"Ahmed","year":"1994","journal-title":"J. Immunol. Methods"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:12:33Z","timestamp":1791407553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826009272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":46,"alternative-id":["S0045206826009272"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110391","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 3-[(5-nitro-2-heteroaryl)methylene]-2-indolinone derivatives as highly potent antileishmanial agents and their bioactivation by NTR1 and 2","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110391","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110391"}}